Discovery and Characterization of Natural Product Systems

NIH RePORTER · NIH · R35 · $381,095 · view on reporter.nih.gov ↗

Abstract

Project Summary. In this competing renewal of R35 GM118101, we propose to focus on investigating and developing biocatalytic systems that generate complex natural products with high potential as therapeutic agents. This program has been highly productive with 34 publications over the past four years. Major progress continues toward studies on the function and structure of modular polyketide synthases (PKSs) from bacteria. A second thematic area involves studies on diverse bacterial and fungal indole alkaloid pathways for which we have reported important achievements on characterizing biosynthetic enzymes that catalyze pericyclic (e. g. Cope, Diels-Alder) reactions. We plan to build on these studies and also expand work on allied tailoring reactions for indole alkaloid structural diversification. Our work in the type I PKS area will focus on function and structure of key catalytic domains that we have identified to be gatekeepers in the catalytic cycle. By employing natural and unnatural advanced polyketide chain elongation intermediates with late stage PKS modules, we plan to develop methods to expand the biocatalytic potential of these remarkable molecular machines for assembly of macrolactone structures. Further glycosylation and late-stage hydroxylation/epoxidation methods will be employed to generate next generation macrolides for testing against a range of antibiotic-resistant human pathogens. Our work in the microbial indole alkaloids will focus on natural products whose core ring systems are derived from biocatalytic pericyclic reactions. Mechanistic understanding of these unusual processes is rapidly emerging, and their apparent flexibility indicates high potential for metabolite structural diversification. These efforts will be augmented by exploring late-stage tailoring enzymes capable of further modifying core indole alkaloid structures to generate a range of biologically active products with significant pharmaceutical potential.

Key facts

NIH application ID
10418743
Project number
5R35GM118101-07
Recipient
UNIVERSITY OF MICHIGAN AT ANN ARBOR
Principal Investigator
DAVID H SHERMAN
Activity code
R35
Funding institute
NIH
Fiscal year
2022
Award amount
$381,095
Award type
5
Project period
2016-06-01 → 2026-05-31